- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02285829
Determination of TOF Test Threshold for Obtaining Reliable Pedicle Screw Stimulation Test During Lumbar Spine Surgery
During lumbar spine fusion surgery intraoperative neurophysiological monitoring is in routine use for prevention of possible nerve injuries during placement of screw into pedicle. Pedicle screw stimulation test is performed to assess if screw placement is encroaching on the nerve roots. Relative distance between the pedicle screw and the neighbouring root can be estimated by the intensity of the current required to activate the root and appropriate muscle. A properly placed screw can be distinguished from those perforating the pedicle wall by its higher minimum level of electrical current needed to elicit a muscle response. The minimum level is deemed as threshold. This test is based on compound muscle action potential (CMAP) and use of neuromuscular blocking agents (NMBA) should be avoided because of possible cause of false negative results of screw stimulation test. Neuromuscular blocking agents, which are in routine use during anesthesia, will have effect on muscle action potential. When NMBA are used current stimulus will depolarize the same number of axons and the associated muscle response will be present but of lower amplitude because some percentage of motor fibers will be blocked by activity of NMBA. At this point, stronger stimulus is needed to recruit additional axons/muscle fibers , and hence, the measured threshold is elevated.
Train of four (TOF) test is method used to determine level of neuromuscular blockade, by stimulation of peripheral nerve and following induced muscle contractions. Interpretation of muscle contractions may be by subjective (visual) or objective (quantitative) method. Quantitative TOF test may be used prior screw stimulation test by calculating T4/T1 ratio and obtaining quantitative value which shows level of neuromuscular blockade. Residual neuromuscular blockade may be present before screw stimulation test, and effect on accuracy of this test in this situation was not clearly investigated in recent studies.
The purpose of this study would be to determine changes of screw stimulation thresholds under different range of neuromuscular blockade.Therefore, acceptable neuromuscular blockade threshold (determined by TOF test) acceptable for obtaining reliable screw stimulation test should be determined. Screw stimulation test may be performed when neuromuscular blockade is absent and compared to repeated screw stimulation test when neuromuscular blockade is present. Different levels of neuromuscular blockade may provide different results on screw stimulation test, so if difference is statistically significant, induced neuromuscular blockade level may be set as threshold value, acceptable for obtaining reliable testing results.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10003
- NYU Langone Medical Center, Hospital for Joint Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects undergoing lumbar spine fusion surgery with neurophysiologic intraoperative monitoring when pedicle screw stimulation test is performed.
- Subjects of both gender
- Age 18-85
- With diagnosis of lumbar spinal stenosis.
- All subjects capable of giving informed consent in order to be included for the study.
Exclusion Criteria:
- Subjects with medical history of presence of neuromuscular disease
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
T4/T1=0.1-0.25
Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium, 0.5 µg/kg/min for Cisatracurium ), and TOF ratios will be monitored every 20 seconds.
T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test.
When TOF ratio ranges 0.1-0.25,
values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
|
Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation.
Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012
mg/kg/min IV.
Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min.
Following recovery and baseline screw stimulation at TOF >0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached.
Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
Other Names:
|
T4/T1=0.25-0.50
Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds.
T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test.
When TOF ratio ranges 0.25-0.50,
values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
|
Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation.
Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012
mg/kg/min IV.
Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min.
Following recovery and baseline screw stimulation at TOF >0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached.
Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
Other Names:
|
T4/T1=0.50-0.75
Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds.
T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test.
When TOF ratio ranges 0.50-0.75,
values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
|
Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation.
Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012
mg/kg/min IV.
Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min.
Following recovery and baseline screw stimulation at TOF >0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached.
Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
Other Names:
|
T4/T1=0.75-0.90
Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds.
T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test.
When TOF ratio ranges 0.75-0.90,
values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
|
Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation.
Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012
mg/kg/min IV.
Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min.
Following recovery and baseline screw stimulation at TOF >0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached.
Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Train of four (TOF) test
Time Frame: TOF test measure will be performed during the day of surgery prior pedicle screw stimulation test
|
T4/T1 ratio will be determined and measured prior pedicle screw stimulation test, during lumbar spine surgery.
Data will be obtained and followed from participants during one day, while surgery is performed.
|
TOF test measure will be performed during the day of surgery prior pedicle screw stimulation test
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aleksandar Beric, MD, Neurologist
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-01568
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromuscular Blockade
-
Hospital Federal de BonsucessoUnknownNeuromuscular Blockade | Magnesium Sulfate | Rocuronium | Deep Neuromuscular BlockadeBrazil
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedNeuromuscular Blockade | Neuromuscular MonitoringItaly
-
Universitair Ziekenhuis BrusselUnknownNeuromuscular Blockade | Neuromuscular MonitoringBelgium
-
Central Hospital, Nancy, FranceNot yet recruitingComparison of the TOFscan and the TetraGraph During Recovery of Neuromuscular Function (DECURAR-EMG)Neuromuscular BlockadeFrance
-
Vanderbilt University Medical CenterUniversity of Pittsburgh; The Cooper Health SystemRecruitingNeuromuscular BlockadeUnited States
-
Leiden University Medical CenterMerck Sharp & Dohme LLCCompletedNeuromuscular BlockadeNetherlands
-
Seoul National University Bundang HospitalCompleted
-
Poitiers University HospitalEnrolling by invitationNeuromuscular BlockadeFrance
-
Centre Hospitalier Universitaire Dinant Godinne...CompletedNeuromuscular BlockadeBelgium
-
Seoul National University HospitalCompletedNeuromuscular BlockadeKorea, Republic of
Clinical Trials on Rocuronium Bromide, Cisatracurium Besylate
-
Northwell HealthTerminatedTotal Knee ReplacementUnited States
-
Fudan UniversityCompletedC.Delivery; Surgery (Previous), Gynecological
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedAcute Respiratory Distress SyndromeUnited States
-
Tianjin Nankai HospitalNot yet recruitingIntra-abdominal Hypertension
-
Pontificia Universidad Catolica de ChileCompletedNeuromuscular Blockade
-
Second Hospital of Shanxi Medical UniversityRecruitingOpioid Analgesic Adverse ReactionChina
-
Sheba Medical CenterUnknown
-
University of Texas Southwestern Medical CenterCompletedRenal Impairment | Neuromuscular BlockadeUnited States
-
Second Affiliated Hospital of Nanchang UniversityYichang Humanwell Pharmaceutical Co., Ltd., ChinaNot yet recruitingAnesthesia, General | Emergence Agitation | Laparoscopic Abdominal Surgery | Remimazolam Besylate | Perioperative SedationChina
-
Thomas SchrickerMerck Sharp & Dohme LLCTerminatedHigh-Frequency Jet Ventilation | Vocal Cord ResectionCanada